Coexistence of SLE,tuberous sclerosis and aggressive natural killer-cell leukaemia: Coincidence or correlated?

Abstract

Get full access to this article

View all access options for this article.

References

Olde Bekkink

Ahmed-Ousenkova

Netea

Van der Velden

Berden

. Coexistence of systemic lupus erythematosus, tuberous sclerosis and aggressive natural killer-cell leukaemia: Coincidence or correlated? Lupus 2016; 25: 766–771.

Singh

Birkenbach

Caza

Perl

Cohen

. Tuberous sclerosis and fulminant lupus in a young woman. J Clin Rheumatol 2013; 19: 134–137.

Katada

Maeda

Yoshimura

. Coincidence of tuberous sclerosis and systemic lupus erythematosus. Mod Rheumatol 2012; 22: S155–S155.

Carrasco Cubero C, Bejarano Moguel V, Fernández Gil MÁ, Álvarez Vega JL. Asociación lupus eritematoso sistémico y esclerosis tuberosa un caso. (Coincidence of tuberous sclerosis and systemic lupus erythematosus: A case report.) Reumatol Clin 2016; 12: 219–222.

Carr Perl A. Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases. Nat Rev Rheumatol 2016; 12: 169–82.

Yap

Tang

Chan

. Proliferation signal inhibitors in the treatment of lupus nephritis: Preliminary experience. Nephrology 2012; 17: 676–680.

US National Library of Medicine. NCT00779194, https://clinical trials.gov/ct2/results?term¼NCT00779194 (accessed 1 June 2016).

Tee

Sampson

Pal

Bateman

. The role of mTOR signalling in neurogenesis, insights from tuberous sclerosis complex. Semin Cell Dev Biol 2016; 52: 12–20.

MacKeigan

Krueger

. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex. Neuro Oncol 2015; 17: 1550–1559.